Neuropathological correlates of age and sex differences in 18F-flortaucipir PET
Year: 2026
Type: article
Study design: Observational Study
Abstract: Among amyloid-positive individuals with symptomatic Alzheimer's disease, older age and male sex have been associated with a lower prevalence of Tau-PET-positivity. Whether Tau-PET-negative older and/or male individuals truly do not harbor widespread tau pathology or whether tangle density is below the PET-detection threshold remains unknown. Therefore, we aimed to investigate the neuropathological correlates of age- and sex-differences in Tau-PET in independent PET-only, autopsy-only, and PET-to-autopsy cohorts. In the PET-only cohort, we included amyloid-β-positive participants with MCI or dementia who underwent [18F]flortaucipir-PET (n=672). In the autopsy-only cohort, we included participants with moderate-to-frequent CERAD scores and MCI or dementia with available data on Braak stage and tangle density (n=945). In the PET-to-autopsy cohort, we included participants who underwent antemortem Tau-PET and had undergone a postmortem assessment of Braak staging (n=85) (median PET-to-post-mortem-interval: 2.6 months). A subset additionally had tangle density data available (n=63). Tau-PET SUVr was calculated in a temporal meta-region, and Tau-PET-positivity was defined using a predefined threshold of 1.36 SUVr. Autopsy cases were categorized as Braak 0-IV versus Braak V-VI. In PET-only-analyses (age: 71.9±8.2, 52.8% male), older age and male sex were associated with a lower prevalence of Tau-PET-positivity and lower Tau-PET SUVr (all p<0.05). In autopsy-only-analyses (age: 82.7±7.9, 54.6% male), older age and male sex were associated with a lower prevalence of Braak-V/VI neuropathology (both p<0.05). Among Braak-V/VI autopsy cases (n=598), older age was associated with lower tangle density (β=-0.38, p<0.001). In PET-to-autopsy-analyses (age: 81.7±9.2, 52.9% male), Tau-PET showed excellent specificity for detecting Braak-V/VI neuropathology (100% across age-stratified and sex-stratified models), while the sensitivity decreased at older age (<83y: 92% [95% confidence interval: 80%-100%] vs ≥83y: 42% [23%-62%]) and in males (females: 85% [69%-96%] vs males: 48% [28%-68%]). Older and male participants with Braak-V/VI neuropathology showed both lower Tau-PET SUVr (age: β=-0.46, p=0.003; sex: β=-0.97, p=0.001), and in the same individuals, older participants showed trend-level lower tangle density (β=-0.31, p=0.053). The lack of age/sex-interactions indicate that the relationship between Tau-PET and tangle density is consistent across ages and sexes. Comprehensive and independent PET, autopsy, and PET-to-autopsy analyses demonstrate that the associations of older age and male sex with lower [18F]flortaucipir-PET uptake and positivity rates can be explained by lower tangle densities. [18F]flortaucipir-PET SUVr thus closely reflects tangle density, which accounts for the lower sensitivity of [18F]flortaucipir-PET for detecting low-density Braak-V/VI tau pathology in older individuals and males.
Source: Brain
Authors: Emma M Coomans, Ruben Smith, Daria Pawlik, Kevin Oliveira Hauer, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Cecilia Tremblay, Geidy E Serrano, Thomas G Beach, Annemieke J Rozemuller, Yolande Pijnenburg, Elsmarieke van de Giessen, Vikas Kotari, Michael Pontecorvo, Sergey Shcherbinin, Oskar Hansson, Rik Ossenkoppele
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,570
Funders: U.S. Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Pfizer, Merck, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, Arizona Department of Health Services, Cure Alzheimer's Fund, BioClinica, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company, Parkinson's Foundation, GHR Foundation, Health~Holland, Noaber Foundation, ZonMw, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Lunds Universitet, Hjärnfonden, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Fujirebio Europe, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Sveriges Regering, Swedish Brain Power, Alzheimerfonden, Familjen Kamprads Stiftelse, Stichting Dioraphte, Alzheimer Nederland, Skånes universitetssjukhus, Servier, H. Lundbeck A/S, IXICO, Grifols, Amsterdam Neuroscience, Stiftelsen Bundy Academy, Eisai Canada, Arizona Biomedical Research Commission, National Institutes of Health, Genentech, GE Healthcare, Bristol-Myers Squibb Canada, AbbVie Canada, Canadian Institutes of Health Research, European Research Council, Horizon 2020, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering, Johnson and Johnson Pharmaceutical Research and Development, Janssen Alzheimer Immunotherapy Research And Development, DoD Alzheimer's Disease Neuroimaging Initiative
Awards: G1321055688, G2088087233, G2465228561, G2541450865, G3497632134, Validering och implementering av ny träffsäker diagnostik av Alzheimers sjukdom i primärvården och på minnesklinik, G3718618909, Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease, G3955935609, G4038479886, G4687139379, G4687921803, G5184609404, G5376167899, G6650554110, G6698537428, G6710522346, Prospective validation of high-performing blood biomarkers and digital cognitive tests in both specialist memory clinic and general primary care settings, Arizona Alzheimer's Disease Core Center, Development of biomarkers in Alzheimer’s disease: improvement of early and accurate diagnosis and increased understanding of disease mechanisms that facilitates drug development, A precision medicine approach for the diagnosis and prognosis of preclinical Alzheimer´s disease with implications for clinical trials, National Brain and Tissue Resource for Parkinson's Disease and Related Disorders, G9000039018, G9000360447, G9000361366, G9000362244, Arizona Alzheimer's Disease Research Center
OpenAlex ID: W7155036853
